Switch theme
Sign up to access all valuation multiples
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
2010
228
LTM Revenue $161M
LTM EBITDA -$106M
$276M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Coherus Oncology has a last 12-month revenue (LTM) of $161M and a last 12-month EBITDA of -$106M.
In the most recent fiscal year, Coherus Oncology achieved revenue of $267M and an EBITDA of $60.9M.
Coherus Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Coherus Oncology valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $161M | XXX | $267M | XXX | XXX | XXX |
| Gross Profit | $96.4M | XXX | $149M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 56% | XXX | XXX | XXX |
| EBITDA | -$106M | XXX | $60.9M | XXX | XXX | XXX |
| EBITDA Margin | -66% | XXX | 23% | XXX | XXX | XXX |
| EBIT | -$128M | XXX | -$112M | XXX | XXX | XXX |
| EBIT Margin | -80% | XXX | -42% | XXX | XXX | XXX |
| Net Profit | -$59.3M | XXX | $28.5M | XXX | XXX | XXX |
| Net Margin | -37% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $139M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Coherus Oncology's stock price is $1.
Coherus Oncology has current market cap of $88.1M, and EV of $276M.
See Coherus Oncology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $276M | $88.1M | XXX | XXX | XXX | XXX | $-0.54 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Coherus Oncology has market cap of $88.1M and EV of $276M.
Coherus Oncology's trades at 1.0x EV/Revenue multiple, and 4.5x EV/EBITDA.
Equity research analysts estimate Coherus Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Coherus Oncology has a P/E ratio of -1.5x.
See valuation multiples for Coherus Oncology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $88.1M | XXX | $88.1M | XXX | XXX | XXX |
| EV (current) | $276M | XXX | $276M | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | -2.6x | XXX | 4.5x | XXX | XXX | XXX |
| EV/EBIT | -2.2x | XXX | -2.5x | XXX | XXX | XXX |
| EV/Gross Profit | 2.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.5x | XXX | 3.1x | XXX | XXX | XXX |
| EV/FCF | -6.7x | XXX | -13.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCoherus Oncology's last 12 month revenue growth is -52%
Coherus Oncology's revenue per employee in the last FY averaged $1.2M, while opex per employee averaged $1.1M for the same period.
Coherus Oncology's rule of 40 is -127% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Coherus Oncology's rule of X is -195% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Coherus Oncology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -52% | XXX | -39% | XXX | XXX | XXX |
| EBITDA Margin | -66% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -127% | XXX | -29% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -195% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 98% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Coherus Oncology acquired XXX companies to date.
Last acquisition by Coherus Oncology was XXXXXXXX, XXXXX XXXXX XXXXXX . Coherus Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Coherus Oncology founded? | Coherus Oncology was founded in 2010. |
| Where is Coherus Oncology headquartered? | Coherus Oncology is headquartered in United States of America. |
| How many employees does Coherus Oncology have? | As of today, Coherus Oncology has 228 employees. |
| Who is the CEO of Coherus Oncology? | Coherus Oncology's CEO is Mr. Dennis M. Lanfear. |
| Is Coherus Oncology publicy listed? | Yes, Coherus Oncology is a public company listed on NAS. |
| What is the stock symbol of Coherus Oncology? | Coherus Oncology trades under CHRS ticker. |
| When did Coherus Oncology go public? | Coherus Oncology went public in 2014. |
| Who are competitors of Coherus Oncology? | Similar companies to Coherus Oncology include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Coherus Oncology? | Coherus Oncology's current market cap is $88.1M |
| What is the current revenue of Coherus Oncology? | Coherus Oncology's last 12 months revenue is $161M. |
| What is the current revenue growth of Coherus Oncology? | Coherus Oncology revenue growth (NTM/LTM) is -52%. |
| What is the current EV/Revenue multiple of Coherus Oncology? | Current revenue multiple of Coherus Oncology is 1.7x. |
| Is Coherus Oncology profitable? | Yes, Coherus Oncology is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Coherus Oncology? | Coherus Oncology's last 12 months EBITDA is -$106M. |
| What is Coherus Oncology's EBITDA margin? | Coherus Oncology's last 12 months EBITDA margin is -66%. |
| What is the current EV/EBITDA multiple of Coherus Oncology? | Current EBITDA multiple of Coherus Oncology is -2.6x. |
| What is the current FCF of Coherus Oncology? | Coherus Oncology's last 12 months FCF is -$41.2M. |
| What is Coherus Oncology's FCF margin? | Coherus Oncology's last 12 months FCF margin is -26%. |
| What is the current EV/FCF multiple of Coherus Oncology? | Current FCF multiple of Coherus Oncology is -6.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
